Literature DB >> 22341663

[Cefoxitin and ESBL].

M Boyer1, A Bignon, R Dessein, K Faure, B Guery, E Kipnis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22341663     DOI： 10.1016/j.medmal.2012.01.004

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN： 0399-077X            Impact factor:   2.152


× No keyword cloud information.
  2 in total

1.  Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli.

Authors:  H Guet-Revillet; A Emirian; M Groh; B Nebbad-Lechani; E Weiss; O Join-Lambert; E Bille; V Jullien; J R Zahar
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

2.  Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study.

Authors:  Paul Chabert; Judith Provoost; Sabine Cohen; Céline Dupieux-Chabert; Laurent Bitker; Tristan Ferry; Sylvain Goutelle; Jean-Christophe Richard
Journal:  Ann Intensive Care       Date:  2022-09-30       Impact factor: 10.318
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.